




RealRate

# MEDICINAL PRODUCTS 2019

## Navidea Biopharmaceuticals Inc. Rank 46 of 50





RealRate

# MEDICINAL PRODUCTS 2019

## Navidea Biopharmaceuticals Inc. Rank 46 of 50



The relative strengths and weaknesses of Navidea Biopharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Navidea Biopharmaceuticals Inc. compared to the market average is the variable Other Expenses, increasing the Economic Capital Ratio by 24% points. The greatest weakness of Navidea Biopharmaceuticals Inc. is the variable Net Income, reducing the Economic Capital Ratio by 206% points.

The company's Economic Capital Ratio, given in the ranking table, is -242%, being 236% points below the market average of -5.9%.

Input Variable	Value in 1000 USD
Assets, Current	5,596
Assets, Non-Current	835
General and Administrative Expense	7,795
Goodwill	428
Liabilities, Current	3,379
Liabilities, Non-Current	64
Other Assets	0
Other Compr. Net Income	1.7
Other Expenses	-9.8
Other Liabilities	1,168
Other Net Income	-5,277
Other Revenues	1,169
Property, Plant and Equipment, Net	162
Research and Development	4,222

Output Variable	Value in 1000 USD
Liabilities	4,611
Assets	7,022
Expenses	12,007
Revenues	1,169
Stockholders Equity	2,410
Net Income	-16,114
Comprehensive Net Income	-16,113
Economic Capital Ratio	-242%